


SUPPLEMENTAL DATA


SUPPLEMENTAL FIGURES

SUPPLEMENTAL FIGURE 1 Dissection of haplotype-dependent *INS* pre-mRNA splicing



Legend: (A) Splicing pattern of reporter constructs mutated at naturally occurring *INS* variants. Mutations are denoted by the traditional nomenclature (<http://www.hgvs.org/mutnomen/>). The original designation (Stead et al. 2003) of the variant is followed in parentheses. RNA products are shown schematically to the right; template reporters for overlap-extension PCR are at the bottom. (B) Predicted auxiliary splicing elements at *INS-72*. Putative splicing regulatory motifs are shown above the sequence; variant residues at *INS-72* are underlined. (C) Splicing pattern of African-specific haplotypes with (Ta, Ma, Ja) or without (Ya, Va, Na) the 4-nt insertion allele at *INS-69*. The IC haplotype is shown as a control. Haplotype designation was as previously described (Stead et al. 2003). (D) Splicing of reporter constructs with (primers J-C) and without (primers A-C) upstream minisatellite (VNTR) sequences is identical. Amplifications shown for panels B and C was with primers PL3 (Kralovicova et al. 2006a) and E. In experiment shown in panel D we employed PCR primers D and PL4 (Kralovicova et al. 2006a) (Figure 1).


SUPPLEMENTAL FIGURE 2 Allele-specific *INS* splicing in mouse cell lines



Legend: (A) Increased IR of the *INS* class IC haplotype as compared to the class IIIA haplotype in the *Aire*-expressing TEC cell line derived from thymic epithelial cells and in the macrophage cell line RAW264; NIH3T3 cells are shown as controls. The *INS* splicing pattern was not significantly different in a TEC cell line lacking *Aire* (data not shown). Haplotypes are at the top of each panel and mRNA isoforms to the right. Cloning primers are shown at the bottom; their location is depicted in Figure 1A. The extended 3' segment of D-F reporters inhibits the cryptic 3' splice site in *INS* exon 3 (cr3'ss+126), which is most likely mediated by the 3'end processing machinery that can influence selection of 3'ss of the last intron (Rigo and Martinson 2008). (B) A proposed model for genetic susceptibility to T1D at *IDDM2*. Unlike *INS-69*, which is confined to Africans, the *INS-27A* allele (IVS1-6A) has a high frequency in whites (Stead et al. 2003), indicating that this variant is critical for the haplotype-dependent proinsulin expression in this population. Antigen presenting cells will have a lower number of the MHC/proinsulin peptide complexes in carriers of the low-expressing and T1D-predisposing A alleles than in carriers of the T alleles. Their lower number would be associated with the lower probability of inducing apoptosis of autoreactive T cells in the thymus during negative selection. Antigen-presenting cells/antigenic peptides are in blue. MHC molecules and T-cell receptors are highlighted in light and dark gray, respectively.

SUPPLEMENTAL FIGURE 3 Heterogenous nuclear RIBONUCLEOPROTEINS F/H in INS intron 1 splicing

Legend: (A) Increased intron 1 retention and decreased utilization of cr3'ss+126 in hnRNP F/H-depleted cells. siRNAs are at the top, RNA products to the right; sc, scrambled control. The final concentration of siRNAs in culture media was 80 (sc), 60 and 100 nM (hnRNP H/F). The D-F constructs used for this experiment contained the class IC haplotype. (B) Improved efficiency of intron 1 removal and cr3'ss+126 activation in cells overexpressing hnRNP H (1 µg of pcDNA-hnRNP-H) and hnRNP F (1 µg of pCI-hnRNP-F). EV, empty vector.



SUPPLEMENTAL FIGURE 4 Sequence alignment of the 5' untranslated region of the proinsulin gene in primates

Legend: Intrinsic sequences are in lower case, exonic sequences are in upper case. Lineage-specific changes observed in at least two species/animals are highlighted in gray. Naturally occurring human polymorphisms are in red. Alignment was carried out using the Clustal-Wallis algorithm (v. 2.0). Hs, *Homo sapiens* (Stead et al. 2003)(Genbank accession numbers AY138590 and L15440); Pt1-2, *Pan troglodytes* (Stead et al. 2003) (this study); Gg, *Gorilla gorilla* (Stead et al. 2003)(AY137500); Pp1-2, *Pongo pygmeus* and *abelii* (AY137503 and AC199962); Hg1, Hg2, *Hylobates gabriellae* (this study); Eryp, *Erythrocebus patas* (this study); Cae, *Chlorocebus aethiops* (X61092); Cc116, *Cercopithecus campbelli* (this study); Cd2A, *Cercopithecus diana* (this study); Ca303, *Cercopithecus ascanius* (this study); Mt114, *Macaca tonkeana* (this study); Mf, *Macaca fuscata* (this study); Mm1,Mm2, *Macaca mulatta* (Indian and Chinese, respectively; this study); Ms, *Macaca sylvanus* (this study); Ph100, *Papio hamydras* (this study); Msp119, Msp102, *Mandrillus sphinx* (this study); Cang, *Colobus angolensis* (this study); Aclaf, *Colobus guereza* (this study); Se117, Se2, *Semnopithecus entellus* (this study); Pn, *Pygathrix nemaeus* (this study); To, *Trachypithecus obscurus* (this study); Ta, *Trachypithecus auratus* (this study); Sv, *Semnopithecus vetulus* (this study); Pm, *Presbytis melalophos* (this study); Nl, *Nasalis larvatus* (this study); Cj, *Callithrix jacchus* (this study); So1, *Saguinus oedipus* (this study); Smid92, *Saguinus midas* (this study); Sfl15, *Saguinus fuscicollis* (this study); Calgo6, *Callimico goeldii* (this study); Aab203, *Aotus azarae* (this study); At, *Aotus trivirgatus* (J02989); Mur, *Microcebus murinus* (Ensembl scaffold sequence, www.ensembl.org). Y, C or T; W, A or T; N, C or G or T or A. Genbank accession numbers of new sequences: GU901169-GU901198.

		G0
Hs	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCATCAAGCAGgtcttttgtgtttccaagg	60
Pt1	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCATCAAGCAGgtct---gttccaagg	56
Pt2	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCATCAAGCAGgtct---gttccaagg	56
Gg	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCATCAAGCAGgtct---gttccaagg	56
Pp1	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCATCAAGCAGgtct---gttccaagg	56
Pp2	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCATCAAGCAGgtct---gttccaagg	56
Hg1	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Hg2	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Eryp	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Cae	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	52
Cc116	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	55
Cd2A	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	55
Ca303	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	55
Mt114	CAACCTCTGGGACAGGCTGCNTCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Mf	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Mm1	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Mm2	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Ms	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Ph100	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Msp119	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Msp102	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Cang	CAACCTCTGGGACAGGCGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Aclaf	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Se117	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Se2	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Pn	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
To	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Ta	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Sv	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Pm	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Nl	CAACCTCTGGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Cj	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
So1	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Smid92	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Sfl15	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Calgo6	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	53
Aab203	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
At	CTCACGCCCCGGACCAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	56
Mur	CAGCCCTCAGGACAGGCTGCATCAGAAGAGGCCAGCAAGCAGgtct---gttccaagg	55


	G1	G2			
Hs	gccttgcgtcagggtgg--ctcagggr-----ttccagggtggctggac	102			
Pt1	gccttgcgtcagggtgg--ctcaggg-----ttccagggtggctggac	98			
Pt2	gccttgcgtcagggtgg--ctcaggg-----ttccagggtggctggac	98			
Gg	gccttgcgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Pp1	gccttgcgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Pp2	gccttgcgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Hg1	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Hg2	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Eryp	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Cae	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	109			
Cc116	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	113			
Cd2A	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	113			
Ca303	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	113			
Mt114	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Mf	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Mm1	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Mm2	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Ms	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Ph100	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Msp119	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Msp102	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Cang	gccttcacgtcagggtgg--ntcagggtgcccacttggggttccagggtggctggac	114			
Aclaf	gccttcacgtcagggtgg--ctcagggtgcccacttggggttccagggtggctggac	114			
Sel17	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----96				
Se2	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----96				
Pn	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----96				
To	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----96				
Ta	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----96				
Sv	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----96				
Pm	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----96				
Nl	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----96				
Cj	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----115				
Sol	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----115				
Smid92	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----115				
Sfl15	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----115				
Calgo6	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----112				
Aab203	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----115				
At	gccttcacgtcagggtgg--ctcagggtgcccacttgggg-----115				
Mur	gccttcacgtcagggtgg-----gggacc-----cgggac 85				
	G3	uORF1	G4	uORF2	G5
Hs	cccaggccc-cagctctgcagcaggagg-acgtgg-ctgggctctgaagcatgtgggg		159		
Pt1	cccaggccc-cagctctgcagcaggagg-acgtgg-ctgggctctgaagcatgtgggg		155		
Pt2	cccaggccc-cagctctgcagcaggagg-acgtgg-ctgggctctgaagcatgtgggg		155		
Gg	cccaggccc-cagctctgcagcaggagg-acgtgg-ctgggctctgaagcatgtgggg		171		
Pp1	cccaggccc-cagctctgcagcaggagg-acgtgg-ctgggctctgaagcatgtgggg		171		
Pp2	cccaggccc-cagctctgcagcaggagg-acgtgg-ctgggctctgaagcatgtgggg		171		
Hg1	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Hg2	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Eryp	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Cae	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		166		
Cc116	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		170		
Cd2A	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		170		
Ca303	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		170		
Mt114	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Mf	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Mm1	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Mm2	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Ms	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Ph100	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Msp119	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Msp102	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Cang	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Aclaf	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		171		
Sel17	-----cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		144		
Se2	-----cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		144		
Pn	-----cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		144		
To	-----cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		144		
Ta	-----cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		144		
Sv	-----cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		144		
Pm	-----cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		144		
Nl	-----cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		144		
Cj	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		168		
Sol	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		168		
Smid92	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		168		
Sfl15	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		168		
Calgo6	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		165		
Aab203	cccaggccc-cagctctgcagcaggagg-ttgtgg-ctgggctctgaagcatgtgggg		161		
At	cccaggccc-cagctctgcagcaggagg-ttgtgg-ctgggctctgaagcatgtgggg		160		
Mur	cccaggccc-cagctctgcagcaggagg-acatgg-ctgggctctgaagcatgtgggg		145		

	G6	G7
Hs	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	219
Pt1	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	215
Pt2	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	214
Gg	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Pp1	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Pp2	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Hg1	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Hg2	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Eryp	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Cae	gtgaaccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	222
Cc116	gtgaaccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	230
Cd2A	gtgaaccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	230
Ca303	gtgaaccctggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	230
Mt114	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Mf	gtaaaggcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Mm1	gtaaaggcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Mm2	gtaaaggcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Ms	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Ph100	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Msp119	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Msp102	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Cang	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Aclaf	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	231
Sel17	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	204
Se2	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	204
Pn	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	204
To	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	204
Ta	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	204
Sv	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	204
Pm	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	204
Nl	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	204
Cj	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	228
Sol	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	228
Smid92	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	228
Sfl15	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	228
Calgo6	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	225
Aab203	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	221
At	gtgagcccaggggcccccaaggcagggcacctggcctttagccctgcctcagccctgcctgt	216
Mur	gagaaggcggtttccggggcaggcgccccccac--gtggcctcagccctgcctgt	203

Hs	cwcccagATCACTGT Y CTT---CTGCCATG	246
Pt1	ctcccagATCACTGT CC TT---CTGCCATG	242
Pt2	ctcccagATCACTGT CC TT---CTGCCATG	241
Gg	ctcccagATCACTGT CC TT---CTGCCATG	258
Pp1	ctcccagATCACTGT CC TT---CTGCCATG	258
Pp2	ctcccagATCACTGT CC TT---CTGCCATG	258
Hg1	ctcccagGTCACTGT CC TT---CGGCCATG	258
Hg2	ctcccagGTCACTGT CC TT---CGGCCATG	258
Eryp	ctcccagGTCACTGT CC TT---CGGCCATG	258
Cae	ctctcagGTCACTGT CC TT---CGGCCATG	249
Cc116	ctcccagGTCACTGT CC TT---CGGCCATG	257
Cd2A	ctcccagGTCACTGT CC TT---CGGCCATG	257
Ca303	ctcccagGTCACTGT CC TT---CGGCCATG	257
Mt114	ctcccagGTCACTGT CC TT---CGGCCATG	258
Mf	ctcccagGTCACTGT CC TT---CGGCCATG	258
Mm1	ctcccagGTCACTGT CC TT---CGGCCATG	258
Mm2	ctcccagGTCACTGT CC TT---CGGCCATG	257
Ms	ctcccagGTCACTGT CC TT---CGGCCATG	258
Ph100	ctcccagGTCACTGT CC TT---TGCCATG	255
Msp119	ctcccagGTCACTGT CC TT---CGGCCATG	258
Msp102	ctcccagGTCACTGT CC TT---CGGCCATG	258
Cang	ctcccagGTCACTGT CC TT---CGGCCATG	258
Aclaf	ctcccagGTCACTGT CC TT---CGGCCATG	258
Sel17	ctcccagGTCACTGT CC TT---CGGCCATG	231
Se2	ctcccagGTCACTGT CC TT---CGGCCATG	231
Pn	ctcccagGTCACTGT CC TT---CGGCCATG	231
To	ctcccagGTCACTGT CC TT---CGGCCATG	231
Ta	ctcccagGTCACTGT CC TT---CGGCCATG	231
Sv	ctcccagGTCACTGT CC TT---CGGCCATG	231
Pm	ctcccagGTCACTGT CC TT---CTGCCATG	231
Nl	ctcccagGTCACTGT CC TT---CGGCCATG	231
Cj	ctcccagGCCGCTGT CC TT---CCACCATG	255
Sol	ctcccagGCCGCTGT CC TT---CCACCATG	255
Smid92	ctcccagGCCGCTGT CC TT---CCACCATG	255
Sfl15	ctcccagGCCGCTGT CC TT---CCACCATG	255
Calgo6	ctcccagGCCGCTGT CC TT---CCACCATG	252
Aab203	ctcccagGCCGCTGT CC TT---CCACCATG	248
At	ctcccagGCCGCTGT CC TT---CCACCATG	243
Mur	ctcccagGCTTTGCCCGCCCCGGCATG	233



SUPPLEMENTAL FIGURE 5 Ancestral deletions of *INS* intron 1 in primates and their effect on splicing

Legend: (A) A colobine-specific, 27-nucleotide deletion in *INS* intron 1. The deleted sequence is shown at the top. (B) Splicing pattern of human reporter constructs with two large deletions that took place during primate evolution. 293T cells were transfected with pCR3.1 containing *INS* segments defined by primers D and C, as shown in Figure 1A. Deletions are at the top and RNA products to the right; M, 100-nt size marker. Total RNA was isolated 48 hours post-transfection, reverse transcribed using oligo-d(T)₁₅ and complementary DNA products were visualized using PCR with vector-specific primers PL3 and PL4 and/or PL3 and E (Kralovicova et al. 2004) (Figure 1A). (C) Relative expression of *INS* isoforms in the wild-type reporter and plasmids containing *Hominini*- and *Colobinae*-specific deletions and their combination. The alignment of intron 1 sequences in primates is shown in Supplemental Figure 4. The 16-nt deletion (ctg ccc cac ttg ggg g) took place after the *Homininae* split ~6-9 million years ago.




SUPPLEMENTAL FIGURE 6 Predicted branch point sequence and polypyrimidine tract in *INS* intron 1 in primates

Legend: Pp, orangutan; Hs, human. Predicted branch point sequence (orange) and polypyrimidine tracts (green) were determined using an algorithm derived from a comparative analysis of these signals that were conserved between human and mouse (Kol et al. 2005). Predicted branch point sequences in the remaining primates (Supplemental Figure 4) were identical to the human sequence.




SUPPLEMENTAL FIGURE 7 Coupled translation and splicing regulation of *INS* expression by upstream open reading frames

Legend: *Upper panel*, the splicing pattern of wild-type (WT; E2+1A) and mutated (E2+1G) reporter constructs 48 hours post-transfection into 293T cells. RNA products are schematically shown to the right; *middle panel*, quantification of mRNA isoforms. *Lower panel*, proinsulin concentration in cultures. Mutations introduced in two upstream open reading frames are shown at the bottom and their location and natural variability in primates is shown in Figure 3. E2+1A (WT) is specific for Great Apes, whereas E2+1G was found in all lower primates.




SUPPLEMENTAL FIGURE 8 Extending translational pathophysiology: gain and loss of upstream open reading frames (uORFs) in disease predisposition

Legend: Splicing mutations in the gene for thrombopoietin (*TPO*) induce exon skipping and a loss of the seventh uORF, leading to derepression of translation, excess of TPO and thrombocytosis (Wiestner et al. 1998) (*upper panel*). In contrast, variants that influence splicing of *INS* intron 1 result in a gain of uORF that curtails translation of intron 1-containing transcripts (*lower panel*). These transcripts are exported from the nucleus to the cytoplasm (Kralovicova et al. 2006a; Wang et al. 1997). Exons are denoted by numbered boxes, introns as lines, uORFs by black rectangles, disease-causing or -predisposing mutations by stars, and the increase (*upper panel*) or decrease (*lower panel*) of translated products by arrows. The degree of translation efficiency corresponds to the vertical size of the indicated arrows.




SUPPLEMENTAL FIGURE 9 RNAi-mediated depletion of U2AF subunits

Legend: Western blot analysis of HeLa cells transfected with siRNAs individually targeting U2AF subunits and their isoforms. Final concentrations of each siRNA in culture media were 10, 33 and 100 nM; a scrambled control (GC content 68%) was added at a final concentration of 48 nM. Antibodies are shown to the right. Lanes 2-4 contain two-, four- and eight-fold dilutions, respectively, of the total cell lysate shown in lane 1.




SUPPLEMENTAL FIGURE 10 U2AF35 is effectively downregulated at low concentrations of the U2AF35ab duplex

Legend: Western blot analysis was performed with antibodies shown to the right. Final concentration of the U2AF35ab siRNA in HeLa cell cultures was 0.1, 0.33, 1.0, 3.3 and 10 nM. sc, scrambled siRNA control (47% GC).




SUPPLEMENTAL FIGURE 11 Selection of dual-specificity splice sites by U2AF35

Legend: (A) Schematics of the splicing pattern and location of primers (arrows) used to detect isoforms that result from the use of the 5'ss or 3'ss in *UBE2C/DIABLO* transcripts. ES, exon skipping. (B) RT-PCR analysis of total RNA extracted from HeLa cells transfected with U2AF35ab siRNA and a scrambled control (sc). Final concentrations of siRNAs are shown at the bottom. M, 100-nt size marker.




SUPPLEMENTAL FIGURE 12 Skipping of short exons in U2AF-depleted cells

Legend: An example of a reporter construct with a short central exon (96 nt). The reporter construct was described previously (Kralovicova et al. 2006b). siRNAs are shown at the top, RNA products to the right, the name of the reporter to the left and utilization of the intron-proximal 3'ss at the bottom.




SUPPLEMENTAL FIGURE 13 Identification of auxiliary splicing sequences in exon 2



Legend: (A) *INS* exon 2 deletion constructs (D-F) on the class IC haplotype background. Deletions are shown as horizontal lines (denoted del1-del20). Mutated residues and two deletions that activated cr3'ss+81 are highlighted in gray. (B) Relative expression (%) of four *INS* mRNA isoforms in each deletion reporter. Error bars indicate s.d. determined from duplicate wells. The utilization of the remaining isoforms was negligible, except for activation of cr3'ss+81 in del3 and del9. (C) Identification of a splicing enhancer in exon 2. Mutations in a putative RESCUE-ESE (Fairbrother et al. 2004) (boxed in panel A) are shown at the top. RNA products are shown to the right and the *INS* reporter at the bottom. (D) A putative structure of the newly identified splicing enhancer in exon 2. Mutations are shown by arrows. (E) Activation of cr3'ss+81 by point mutations at exon positions 5, 10 and 11. Mutated positions are highlighted in gray in panel (A). M, 100-nt size marker. (F) Secreted proinsulin is shown on the pmol/L scale. Error bars denote standard deviations of a single transfection experiment in duplicate.

SUPPLEMENTAL FIGURE 14 Coexpression of SR proteins/hnRNPs and *INS* in 293T cells

Legend: Individual SR proteins/hnRNPs are shown at the top, RNA products to the right. Reduction of exon skipping upon individual overexpression of SR proteins is highlighted. An increase of cr3'ss+126 utilization observed for a subset of hnRNPs is also boxed.



SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1 Phylogeneny of G runs in *INS* intron 1 in primates

G run	Great Apes	Old World Monkeys	New World Monkeys	<i>Strepsirrhini</i>
G0	x	x	x	x
G1	x	x	x ¹	
G2	x	x ²		
G3	x	x	x ^{1,3}	x
G4	x	x	x	
G5	x ⁴	x ⁵	x ⁶	x ⁴
G6	x ⁷	x ⁸	x ⁷	x ⁷
G7	x	x	x	x

Legend: G runs are numbered as in Supplemental Figure 4. ‘x’ denotes a conserved G run. ¹, G run was shifted by 1 nucleotide in a subset of New World Monkeys; ², G run was deleted in all examined genera of Asian colobines; ³, extra G₃ in the vicinity; ⁴, G₅; ⁵, G₅, except for *Cercopithecini*; ⁶ G₄; ⁷, G₄; ⁸ G₄, except for *Colobinae*.

SUPPLEMENTAL TABLE 2 Predicted strength of *INS* splice sites

Intron	Splice site ¹	Consensus sequence ²	Maximum entropy score (allele) ³
1	5'ss	CAG/ <u>GT</u> CTKT	6.84 (<i>INS</i> -69del), 2.36 (<i>INS</i> -69ins)
1	Cr5'ss+30	CAG/ <u>GT</u> GGRC	8.07 (<i>INS</i> -26G), 3.09 (<i>INS</i> -26A)
1	3'ss	CAGCCCTGCCTGTCWCCC <u>AG</u> /ATC	7.57 (<i>INS</i> -27T), 4.75 (<i>INS</i> -27A)
1	Cr3'ss+81	CCTCTGGGGACCTGACCC <u>AG</u> /CCG	-1.12
2	5'ss	AGG/ <u>GT</u> GAGC	7.75
2	3'ss	TGCGCGGCACGTCC <u>AG</u> /TGG	4.36
2	Cr3'ss+35	GGGCGGGGGCC <u>AG</u> /GCA	1.54
2	Cr3'ss+126	GCATCTGCTCC <u>CTACCAG</u> /CTG	8.24

Legend: ¹Cryptic (Cr) splice sites are denoted by their exon/intron position (in nucleotides) relative to their authentic counterparts; ², IUB codes: K is G or T, R is A or G, W is A or T. GT and AG dinucleotides are underlined. Exon/intron boundaries are denoted by a slash. ³, Maximum entropy scores were computed as described (Buratti et al. 2007; Vorechovsky 2006; Yeo and Burge 2004). Location of the three variants is shown in Figure 1A. Their designation is according to the previously published nomenclature (Stead et al. 2003); del/ins, 4-nucleotide deletion/insertion allele at *INS*-69. The composite score of intron 1 splice sites is 11.59/14.41 (haplotype I/III, respectively), which is comparable to the composite score of intron 2 splice sites (12.01).

SUPPLEMENTAL TABLE 3 Oligonucleotide primers amplifying competing 3'ss in endogenous transcripts

Gene	Exon	ID# ¹	Primers (5'-3')	Size of PCR products	Distance between competing 3'ss
<i>SERBP1</i>	5	Far2	CTCACAACTGGGAACGTGTC TGTCTGCCACTGGATGATGTT	102/147	45
<i>SRRM1</i>	6	Far3	AAAAAAGGGAGCGGTCTCGTA AAGTAGCCTTGTACTGAA	138/228	90
<i>SLC15A4</i>	3	Far12	CTGTTCCCAGAACGGAAGTG GAAAACAGGGACAATCTGA	114/172	58
<i>CIT</i>	30	Far13	TGAAAATGGAAGGCACATT GAAGGGCTTCCTCTAGCTCT	165/210	45
<i>LRRC28</i>	6	Far15	GGATCTTAGTGACAATGCCT AAGTGGCAAAAATGCAAGAC	226/321	95
<i>SEPT4</i>	11	Far19	GGACCTGAAGGATGTGACAC CCTCATCTTCTCTCGGATA	144/197	53
<i>STAT3</i>	23	Far20	CGCTGCCCATACCTGAAGA TGAGGGTTCAAGCACCTTCAC	89/139	50
<i>ATP13A1</i>	14	Far24	GGAGGTGACCCAGTGTCCA TACGAGGCAAGCACGGACAT	182/252	70
<i>FAM134A</i>	4	Far25	CCTTCTTCCTACTCAGCGTC GCTGGATTCTGCCTCTTGTAA	156/244	88
<i>MAP4K4</i>	11	Far27	GAAGAGGAGCAGCGGCACCT CTCGGTCAAGCAGGCTCGTAG	187/280	93
<i>C20orf30</i>	3	Far28	TTATGATGCCGTCCCGTACC CCTTTGCTGATGTAGCCTGA	135/223	88
<i>SLC35C2</i>	3	Far29	TTTGTGGAAGGCGGTGTTGA CCCAGCTCAGCACCACACGG	141/212	71
<i>SFRS15</i>	19	Far30	CCTCACACTCCACCAATAAG GTGAAACAGGCTGGGTTACA	151/217	66
<i>FMR1-201</i>	15	E15	GACGCGGTCTGGATATACTT CCTCCACGCCCGCGTCCGT	85/124/160	39/36
<i>FMR1-201</i>	16	E16	GTAATCCAAGAGAGGCTAAAG TTGCTGACCATCCACGCTGTC	134/185	51
<i>ECM1</i> ²	4	Far1	CCCCACCCCTATCCCGAAC GGGAGTTGGGCAGGTAGCAG	148/235	87
<i>SPOPL</i> ²	4	Far26	AGGAAATGGGTGAAGTGTAA TTGTTTCTTCCTTTAGCA	136/207	71
<i>PRP3</i> ²	12	Far4	TTTGATGCGAGTATTAGGAA TTTTAATTTCTTGACCTTT	155/213	58
<i>EIF3S7</i> ²	15	-	CTGATGGCACCTTCAGCTCT CCTCGTAGTCTCGGTGAAAG	127/295	168
<i>PTK9</i> ²	12	-	GAGGAGCAGGCCACTTCCTG CTCCACTGTCCCAGCTCTTC	128/247	119
<i>CUEDC1</i>	17	-	GCCTGCGAGAAGGACAGTAA TCGGTTCTCAAGCACCACCT	141/213	72

Legend: ¹, Identity number corresponding to a previously described set of tandem 3'ss separated by >39 nt (Akerman and Mandel-Gutfreund 2007). ², PCR products did not show the predicted size or failed to amplify.

SUPPLEMENTAL TABLE 4 Selection of competing 3'ss upon depletion of U2AF subunits

Gene	ID 3'ss ⁴	ID 3'ss in U2AF35(-) ⁵	3'ss promoted in	ID 3'ss in U2AF65(-)	3'ss promoted in U2AF65(-) cells	Intron- proximal	Intron-distal 3'ss (ME score)	Splice site more dependent on U2AF
			U2AF35(-) cells			3'ss (ME score)		
<i>MAP4K4</i> ^l	50	39	Intron-proximal	38	Intron-proximal	AAG/G (7.8)	CAG/C (9.6)	Intron-distal (stronger)
<i>SLC35C2</i> ^l	12	51	Intron-distal	63	Intron-distal	CAG/A (5.7)	CAG/G (8.9)	Intron-proximal (weaker)
<i>SRRM1</i> ^l	10	1	Intron-proximal	1	Intron-proximal	TAG/A (4.5)	CAG/A (7.4)	Intron-distal (stronger)
<i>FMRI-201</i> ^l	17	8	Intron-proximal	9	Intron-proximal	TAG/G (7.4)	TAG/C (-0.7)	Intron-distal (weaker)
						CAG/A (4.0)		
<i>CUEDCI</i> ^l	82	90	Intron-distal	88	Intron-distal	CAG/G (8.3)	CAG/A (0.8)	Intron-proximal (weaker)
<i>UBE2C</i> ^{l,2}	78	90	Intron-distal	N.D.	N.D.	AAG/G (3.0)	CAG/G (6.7)	Intron-proximal (weaker)
<i>DIABLO</i> ^{l,2}	65	60	Intron-proximal	N.D.	N.D.	TAG/G (10.4)	CAG/G (8.8)	Intron-distal (weaker)
<i>INS intron 1(cr3'ss+8I)</i> ³	0	19	Intron-distal	0	N.I.	CAG/A (4.8)	CAG/C (-1.1)	Intron-proximal (stronger)
<i>INS intron 2(cr3'ss+126)</i> ³	15 (IC D-F) ⁶	0 (IC D-F) ⁶	Intron-proximal	2 (IC D-F) ⁶	Intron-proximal	CAG/T (4.4)	CAG/C (8.2)	Intron-distal (stronger)
	55 (IC D-C) ⁶	3 (IC D-C) ⁶		9 (IC D-C) ⁶				
<i>LIPC (ESS13, SS63)</i> ^l	54	40	Intron-proximal	38	Intron-proximal	TAG/A (6.2)	CAG/T (-2.3)	Intron-distal (weaker)
<i>TH-BP-C</i> ³	95	78	Intron-proximal	45	Intron-proximal	CAG/G (5.2)	CAG/C (5.1)	Intron-distal (weaker)

Legend: ¹, endogenous transcripts; ², dual-specificity splice sites (Zhang et al. 2007); ³, exogenous transcripts; *LIPC* and *TH* minigenes were described previously (Kralovicova et al. 2006b; Kralovicova and Vorechovsky 2007); ⁴, % of splicing to intron-distal 3'ss in untreated cells; ⁵, % of splicing to intron-distal 3'ss in U2AF35-deficient (-) cells; ⁶, haplotype and primers used for minigene cloning are in parentheses. N.I., not informative; N.D., not determined; ME (maximum entropy) scores were computed as described previously (Buratti et al. 2007; Vorechovsky 2006; Yeo and Burge 2004).

SUPPLEMENTAL TABLE 5 A list of synthetic small interfering RNAs

Target	siRNA	Source
U2AF35a	CCAUUGCCCUCUUGAACAU	(Pacheco et al. 2006)
U2AF35b	CCAUCUUGAUUCAAAACAU	(Pacheco et al. 2006)
hU2AF35ab	GGCUGUGAUUGACUUGAAU	(Pacheco et al. 2006)
U2AF35-UTR	AGUGUUGUAGUUGAUUGAC	This study
U2AF26-UTR	AGCCCCCUUCACUCUCCUG	This study
U2AF26-83	GGACAAGGUUAACUGCUCU	This study
U2AF65K	GCAAGUACGGGCUUUGUCAA	(Hastings et al. 2007)
U2AF65P	GCACGGUGGACUGAUUCGU	(Pacheco et al. 2006)
PUF60	GCAGAUGAACUCGGUGAUG	(Hastings et al. 2007)
nPTB-N1	GAGAGGAUCUGACGAACUA	(Spellman et al. 2007)
nPTB-N3	UAAGAAACCUGGAUCCAAA	(Spellman et al. 2007)
PTB	CUUCCAUCAUUCAGAGAA	(Wollerton et al. 2004)
9G8-Gao	AGAUCAAGAUCCAGGUCUA	(Gao et al. 2007)
9G8-UTR	GGGAUUUGUGAUGUCUGUA	This study
9G8-UTR2	GUGUAACCUAGGAAAGAU	This study
SRp75-1	AGACCAAGCUGAAGAGAAG	This study
SRp75-2	AGCAGUCAUUCUAAGAGUA	This study
SRp55-1	GCAGAUCUAAGGAUGAGUA	This study
SRp55-2	AAGAUGAGGCUCUAAGGAA	This study
SRp40-1	UGCUCACCUGUAAGAACAA	This study
SRp40-2	ACGUGGUUCUCAAGUAGA	This study
SRp30c	AGAGGAUGCUAUUAUGGA	(Paradis et al. 2007)
SRp30b/SC35	AAUCCAGGUCGCGAUCGAA	(Gabut et al. 2005),
SRp30b/SC35	CAAGCAACUGGCCUAUUGAA	This study
SRp30a/ASF	ACGAUUGCCGCAUCUACGU	(Karni et al. 2007)
SRp20-1	GGAAAUAAGAACAGUUUG	(Bedard et al. 2007)
SRp20-2	GGUCCCUUUCUAGAGAUAG	(Bedard et al. 2007)
RSRC1-ORF1	GAACCGUAGUCGGUCUCG	This study
RSRC1-ORF2	UGGGCAGUCCUGUGGCCUA	This study
Scrambled control (47% CG)	AGGUAGUGUAACUGCCUUG	This study
Scrambled control (68% CG)	UGCGCUAGGCCUCGGUUGC	This study
hnRNP H	UCAGAAGAUGAACGUAAAU	(Paul et al. 2006)
hnRNP-F	GCGACCGAGAACGACAUUU	(Garneau et al. 2005)
Tra2 α -UTR	CGGAAUGGUUGCAAUUAAG	This study
Tra2 β -UTR	GCAUGAAGACUUUCUGAAA	This study
ZRSR1/2	CAACAAUCAGAACAGAGA	This study
ZRSR2-UTR	GGCUAUGAACGCAGAUGGG	This study
CAPER α -UTR	GGAUCUACUGUCAUUUGUA	This study
CAPER β -UTR	UCAGUGGCACAGUAUACUG	This study
hSlu7-ORF	GUGAGUAUGCUGGAGAUA	This study
hSlu7-UTR	GACCAUCCAAGAUAGAUGC	This study

References to Supplemental material

- Akerman M, Mandel-Gutfreund Y (2007) Does distance matter? Variations in alternative 3' splicing regulation. *Nucleic Acids Res* 35:5487-5498
- Bedard KM, Daijogo S, Semler BL (2007) A nucleo-cytoplasmic SR protein functions in viral IRES-mediated translation initiation. *EMBO J* 26:459-467
- Buratti E, Chivers MC, Kralovicova J, Romano M, Baralle M, Krainer AR, Vorechovsky I (2007) Aberrant 5' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. *Nucleic Acids Res* 35:4250-4263
- Fairbrother WG, Yeo GW, Yeh R, Goldstein P, Mawson M, Sharp PA, Burge CB (2004) RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons. *Nucleic Acids Res* 32:W187-190
- Gabut M, Mine M, Marsac C, Brivet M, Tazi J, Soret J (2005) The SR protein SC35 is responsible for aberrant splicing of the E1alpha pyruvate dehydrogenase mRNA in a case of mental retardation with lactic acidosis. *Mol Cell Biol* 25:3286-3294
- Gao L, Wang J, Wang Y, Andreadis A (2007) SR protein 9G8 modulates splicing of tau exon 10 via its proximal downstream intron, a clustering region for frontotemporal dementia mutations. *Mol Cell Neurosci* 34:48-58
- Garneau D, Revil T, Fisette JF, Chabot B (2005) Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. *J Biol Chem* 280:22641-22650
- Hastings ML, Allemand E, Duelli DM, Myers MP, Krainer AR (2007) Control of pre-mRNA splicing by the general splicing factors PUF60 and U2AF. *PLoS ONE* 2:e538
- Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. *Nat Struct Mol Biol* 14:185-193
- Kol G, Lev-Maor G, Ast G (2005) Human-mouse comparative analysis reveals that branch-site plasticity contributes to splicing regulation. *Hum Mol Genet* 14:1559-1568
- Kralovicova J, Gaunt TR, Rodriguez S, Wood PJ, Day INM, Vorechovsky I (2006a) Variants in the human insulin gene that affect pre-mRNA splicing: is -23Hphi a functional single nucleotide polymorphism at *IDDM2*? *Diabetes* 55:260-264
- Kralovicova J, Haixin L, Vorechovsky I (2006b) Phenotypic consequences of branchpoint substitutions. *Hum Mutat* 27:803-813
- Kralovicova J, Houngninou-Molango S, Kramer A, Vorechovsky I (2004) Branch sites haplotypes that control alternative splicing. *Hum Mol Genet* 13:3189-3202
- Kralovicova J, Vorechovsky I (2007) Global control of aberrant splice site activation by auxiliary splicing sequences: evidence for a gradient in exon and intron definition. *Nucleic Acids Res* 35:6399-6413
- Pacheco TR, Coelho MB, Desterro JM, Mollet I, Carmo-Fonseca M (2006) In vivo requirement of the small subunit of U2AF for recognition of a weak 3' splice site. *Mol Cell Biol* 26:8183-8190
- Paradis C, Cloutier P, Shkreta L, Toutant J, Klarskov K, Chabot B (2007) hnRNP I/PTB can antagonize the splicing repressor activity of SRp30c. *RNA* 13:1287-1300
- Paul S, Dansithong W, Kim D, Rossi J, Webster NJ, Comai L, Reddy S (2006) Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing. *EMBO J* 25:4271-4283
- Rigo F, Martinson HG (2008) Functional coupling of last-intron splicing and 3'-end processing to transcription in vitro: the poly(A) signal couples to splicing before committing to cleavage. *Mol Cell Biol* 28:849-862
- Spellman R, Llorian M, Smith CW (2007) Crossregulation and functional redundancy between the splicing regulator PTB and its paralogs nPTB and ROD1. *Mol Cell* 27:420-434
- Stead JD, Hurles ME, Jeffreys AJ (2003) Global haplotype diversity in the human insulin gene region. *Genome Res* 13:2101-2111
- Vorechovsky I (2006) Aberrant 3' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. *Nucleic Acids Res* 34:4630-4641
- Wang J, Shen L, Najafi H, Kolberg J, Matschinsky FM, Urdea M, German M (1997) Regulation of insulin preRNA splicing by glucose. *Proc Natl Acad Sci USA* 94:4360-4365
- Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC (1998) An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. *Nat Genet* 18:49-52
- Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA, Smith CW (2004) Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. *Mol Cell* 13:91-100
- Yeo G, Burge CB (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J Comput Biol* 11:377-394

Zhang C, Hastings ML, Krainer AR, Zhang MQ (2007) Dual-specificity splice sites function alternatively as 5' and 3' splice sites. Proc Natl Acad Sci USA 104:15028-15033